SCHEMBL4920170

SCHEMBL4920170

Cc1cc(NC(=O)Nc2ccc(F)cc2)ccc1F

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 10/20 0.67
RAB9A P51151 10/20 0.67
SMN1; SMN2 Q16637 6/20 0.67
KMT2A Q03164 7/20 0.58
MEN1 O00255 6/20 0.58
HTT P42858 4/20 0.58
LMNA P02545 1/20 0.58
MAPT P10636 3/20 0.56
MAPK1 P28482 2/20 0.56
XBP1 P17861 1/20 0.56
IDH1 O75874 1/20 0.56
ALDH1A1 P00352 1/20 0.55
CYP1A2 P05177 1/20 0.55
CYP2C9 P11712 1/20 0.55
CYP2C19 P33261 1/20 0.55
TAAR1 Q96RJ0 1/20 0.54
POLB P06746 1/20 0.54
TP53 P04637 2/20 0.54
BLM P54132 1/20 0.53
CASP3 P42574 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4112716 0.88 RAB9A (0.73) NPC1RAB9ASMN1; SMN2KMT2AMEN1
SCHEMBL4112443 0.86 NPC1 (0.71) NPC1RAB9ASMN1; SMN2KMT2AMEN1
SCHEMBL4112064 0.86 NPC1 (0.62) NPC1RAB9ASMN1; SMN2KMT2AMEN1
SCHEMBL4113200 0.85 MAPT (0.61) NPC1RAB9ASMN1; SMN2KMT2AMEN1
SCHEMBL15172131 0.84 ALDH1A1 (0.55) NPC1RAB9ASMN1; SMN2KMT2AMEN1
SCHEMBL29824382 0.84 ALDH1A1 (0.55) NPC1RAB9ASMN1; SMN2KMT2AMEN1
SCHEMBL4127751 0.84 RAB9A (0.56) NPC1RAB9ASMN1; SMN2KMT2AMEN1
SCHEMBL13853041 0.82 NPC1 (0.61) NPC1RAB9ASMN1; SMN2KMT2AMEN1
SCHEMBL4111450 0.82 MEN1 (0.50) NPC1RAB9ASMN1; SMN2KMT2AMEN1
SCHEMBL4121462 0.82 MEN1 (0.50) NPC1RAB9ASMN1; SMN2KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120214808-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LIMITED (GB) 2012-08-23 US claimed
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LTD. (GB) 2008-10-23 US claimed
US-20120214808-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LIMITED (GB) 2012-08-23 US disclosed
US-20120214808-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LIMITED (GB) 2012-08-23 US disclosed
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LTD. (GB) 2008-10-23 US disclosed
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LTD. (GB) 2008-10-23 US disclosed
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LTD. (GB) 2008-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity CNR1, GPR119, UTS2R NPC1 148/4885RAB9A 3359/4885SMN1; SMN2 3931/4885
US-20120214808-A1 Aryl Urea Derivatives for Treating Obesity CNR1, GPR119, UTS2R NPC1 148/4885RAB9A 3359/4885SMN1; SMN2 3931/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.